Estudo randomizado | Em pacientes com carcinoma esofágico de células escamosas avançado, tanto o nivolumabe com quimioterapia quanto o nivolumabe com ipilimumabe resultaram em sobrevida geral mais longa do que a quimioterapia isolada.

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário (Reunião anual da ASCO 2021): Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab as First-Line Treatment for Patients With Advanced Esophageal Cancer – The ASCO Post

Comentário no Twitter

First-line treatment of advanced esophageal squamous-cell carcinoma with either nivolumab plus chemo or nivolumab plus ipilimumab resulted in a significant overall survival benefit and durable responses as compared with chemo alone. https://t.co/a000bDsh1N pic.twitter.com/NuY2eX58gp

— NEJM (@NEJM) February 2, 2022